Which medications in the drug class Antineoplastics, Monoclonal Antibody are used in the treatment of Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis)?

Updated: Aug 31, 2021
  • Author: Christopher L Tracy, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Antineoplastics, Monoclonal Antibody

Rituximab gained FDA approval for GPA in adults in 2011 and for children aged 2 years or older in 2019. It is an alternative to cyclophosphamide for induction of remission.

Rituximab (Rituxan)

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. It is indicated in combination with glucocorticoids for treatment of adult and pediatric patients aged 2 years or older with granulomatosis with polyangiitis (GPA; Wegener granulomatosis) or microscopic polyangiitis (MPA).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!